ArticleJournal of clinical microbiology2011
LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection.
Article in Journal of clinical microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 185 citations in OpenAlex.
- The novel prophage lysin Lys1459 exhibits broad-spectrum antibacterial activity via triple-binding domain.Applied and environmental microbiology · 2026Article
- Harnessing lytic phages for biofilm control in carbapenem-resistantMicrobiology spectrum · 2026Article
- Antimicrobial and antibiofilm activity of a novel bacteriophage endolysin (LysSW21) against methicillin-resistant Staphylococcus aureus.BMC microbiology · 2026Article
- A comprehensive review of emerging therapeutic strategies against methicillin-resistantFrontiers in microbiology · 2026Review
- Biofilm-associated genes inFrontiers in microbiology · 2026Review
- Phage endolysins as alternative antimicrobials: mechanisms, clinical progress, and emerging resistance frameworks.Frontiers in microbiology · 2026Review
- Next-generation antimicrobials: A review of phage lysins as precision weapons against drug-resistant pathogens.Virulence · 2025Review
- Bacteriophages and Endolysins Used in the Biocontrol ofMicroorganisms · 2025Review
- Article
- The change of long tail fibers expanded the host range of a T5-like Salmonella phage and its application in milk.BMC microbiology · 2025Article
- Development of a novel chimeric lysin to combine parental phage lysin and cefquinome for preventing sow endometritis after artificial insemination.Veterinary research · 2025Article
- Therapeutic efficacy of LysGH15 against necrotising pneumonia caused byFrontiers in veterinary science · 2025Article
- Heterodimerization of staphylococcal phage φ2638A endolysin isoforms and their functional role in bacterial lysis.microLife · 2025Article
- Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications.Infectious diseases and therapy · 2025Review
- Characterization and bioinformatic analysis of a new chimeric endolysin against MRSA with great stability.AMB Express · 2024Article
- Isolation, whole genome sequencing and application of a broad-spectrum Salmonella phage.Archives of microbiology · 2024Article
- Guiding antibiotics towards their target using bacteriophage proteins.Nature communications · 2024Article
- LysSYL: a broad-spectrum phage endolysin targeting Staphylococcus species and eradicating S. aureus biofilms.Microbial cell factories · 2024Article
- Article
- Biologic and genomic characterization of a novel virulentFrontiers in veterinary science · 2024Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage-coded lysin is an enzyme that destroys the cell walls of bacteria. Phage lysin could be an alternative to conventional antibiotic therapy against pathogens that are resistant to multiple antibiotics. In this study, a novel staphylococcal phage, GH15, was isolated, and the endogenous lytic enzyme (LysGH15) was expressed and purified. The lysin LysGH15 displayed a broad lytic spectrum; in vitro treatment killed a number of Staphylococcus aureus strains rapidly and completely, including methicillin-resistant S. aureus (MRSA). In animal experiments, a single intraperitoneal injection of LysGH15 (50 μg) administered 1 h after MRSA injections at double the minimum lethal dose was sufficient to protect mice (P < 0.01). Bacteremia in unprotected mice reached colony counts of about 10(7) CFU/ml within 3.5 h after challenge, whereas the mean colony count in lysin-protected mice was less than 10(4) CFU/ml (and ultimately became undetectable). These results indicate that LysGH15 can kill S. aureus in vitro and can protect mice efficiently from bacteremia in vivo. The phage lysin LysGH15 might be an alternative treatment strategy for infections caused by MRSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.